HELION BIOTECH ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  11.8% 8.4% 9.1% 9.8% 22.0%  
Credit score (0-100)  21 29 26 24 3  
Credit rating  BB BB BB BB B  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  -18.1 34.1 54.8 33.2 25.7  
EBITDA  -18.1 34.1 17.5 33.2 25.7  
EBIT  -18.1 34.1 17.5 33.2 -65.2  
Pre-tax profit (PTP)  -22.8 31.1 14.6 31.1 -63.9  
Net earnings  -22.8 28.2 11.2 21.6 -48.2  
Pre-tax profit without non-rec. items  -22.8 31.1 14.6 31.1 -63.9  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  181 209 220 242 193  
Interest-bearing liabilities  10.3 10.3 24.2 39.4 24.0  
Balance sheet total (assets)  576 535 456 415 251  

Net Debt  -488 -431 -312 -280 -218  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -18.1 34.1 54.8 33.2 25.7  
Gross profit growth  0.0% 0.0% 60.7% -39.4% -22.6%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  576 535 456 415 251  
Balance sheet change%  -48.1% -7.1% -14.8% -8.9% -39.5%  
Added value  -18.1 34.1 17.5 33.2 25.7  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  60 20 7 4 -182  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -1.0 1.0 2.0 3.0 -1.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 100.0% 31.8% 100.0% -253.6%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -2.1% 6.1% 3.5% 7.7% -19.2%  
ROI %  -4.8% 16.5% 7.4% 12.3% -24.9%  
ROE %  -6.1% 14.5% 5.2% 9.3% -22.1%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  85.1% 79.7% 80.5% 74.7% 77.0%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  2,698.7% -1,262.4% -1,788.5% -841.9% -848.2%  
Gearing %  5.7% 4.9% 11.0% 16.3% 12.4%  
Net interest  0 0 0 0 0  
Financing costs %  67.4% 29.2% 16.8% 8.0% 0.0%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  16.4 9.1 7.9 4.9 4.4  
Current Ratio  1.3 1.4 1.6 2.1 4.4  
Cash and cash equivalent  498.6 440.8 336.3 319.0 242.0  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  120.7 131.8 139.5 166.5 193.4  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0